# US Oncology Drugs Market > U.S. Oncology Drugs Market Research Report Information By Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Other), By Application (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory or Lung Cancer, Other)–Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 14.2% - **2024:** $ 40.29 Billion - **2025:** $ 46.01 Billion - **2035:** $ 173.63 Billion - **Key Players:** Roche (CH), Bristol Myers Squibb (US), Merck & Co (US), Novartis (CH), Pfizer (US), AstraZeneca (GB), Johnson & Johnson (US), Amgen (US), Gilead Sciences (US) **Report ID:** MRFR/Pharma/13148-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-oncology-drugs-market-14675 --- ## Market Summary ## **U.S. Oncology Drugs Market Overview** U.S. Oncology Drugs Market Sizewas valued at USD 98.8 billion in 2022. The U.S. Oncology Drugs market industry is projected to grow from USD 114.1 Billion in 2023 to USD 361.4 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.50% during the forecast period (2023 - 2032).The rise in the prevalence of cancer disease and the rise in the incidence of various cancer conditions are the main market drivers anticipated to propel the U.S. Oncology Drugs market in the United States. Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **U.S. Oncology Drugs Market Trends** ### **Immunotherapy Dominance is driving the market growth** One prominent trend in the U.S. Oncology Drugs market is the dominance of Immunotherapy. Immunotherapeutic agents, including immune checkpoint inhibitors and CAR-T cell therapies, have revolutionized cancer treatment by leveraging the body's immune system to target and eliminate cancer cells. The success of immunotherapy in various cancers, such as melanoma, lung cancer, and haematological malignancies, has led to its widespread adoption and ongoing research for expanding its applications. The trend highlights a paradigm shift towards precision medicine and targeted therapies that offer more effective and less toxic treatment options, representing a significant advancement in the landscape of oncology drugs.This factor drives the market CAGR. Furthermore, another key trend shaping the U.S. Oncology Drugs market is the increasing focus on personalized medicine and targeted therapies. Advances in genomics and molecular diagnostics have allowed for a deeper understanding of the genetic basis of cancer, leading to the development of drugs that target specific molecular pathways involved in cancer growth. Targeted therapies offer the potential for more effective treatment with fewer side effects compared to traditional chemotherapy. The trend towards precision medicine is evident in the growing number of oncology drugs designed to target specific genetic mutations or proteins associated with particular cancer types. This approach improves treatment outcomes and underscores the ongoing evolution towards more tailored and patient-centric cancer care in the United States.Thus driving the U.S. Oncology Drugs market revenue. ## **U.S. Oncology Drugs Market Segment Insights** ### **U.S. Oncology Drugs Type Insights** Based on Type, the U.S. Oncology Drugs market segmentation includes Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, and Others. Targeted therapy emerges as the dominant category in the U.S. Oncology Drugs market due to its emphasis on precision medicine and the specific targeting of molecular pathways involved in cancer growth. These therapies are designed to interfere with specific molecules involved in cancer progression, addressing the unique characteristics of cancer cells. Additionally, immunotherapy, specifically biologic therapy, represents the fastest-growing category in the U.S. oncology drugs market, driven by its revolutionary approach and broad applicability across different cancer types. Biologic therapies harness the body's immune system to recognize and attack cancer cells, offering a novel and powerful treatment approach. **Figure1:U.S. Oncology Drugs Market, by Distribution Channel, 2022 & 2032 (USD Billion)** **** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **U.S. Oncology Drugs Application Insights** The U.S. Oncology Drugs market segmentation, based on Application, includes Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory or Lung Cancer, and others. Breast cancer stands out as the dominant category in the U.S. Oncology Drugs market, driven by its high incidence rate and the comprehensive treatment landscape that includes a diverse array of therapeutic interventions. The prevalence of breast cancer across various demographics necessitates a robust pharmaceutical response, leading to the development of targeted therapies, hormonal treatments, and immunotherapies specifically tailored to address different subtypes of breast cancer. Additionally, immunotherapy is the fastest-growing category in the U.S. oncology drugs market, which is applied to respiratory or lung cancer. Advancements in immunotherapeutic approaches, particularly in non-small cell lung cancer, have led to a surge in research and the development of novel drugs. Immunotherapy has demonstrated unprecedented success in improving survival rates for lung cancer patients, with immune checkpoint inhibitors such as pembrolizumab and nivolumab gaining widespread adoption. ### **U.S. Oncology Drugs Country Insights** In the United States, the Oncology Drugs landscape reflects a dynamic and evolving approach to combating various cancer types. With breast cancer dominating due to its high incidence, the pharmaceutical focus is comprehensive, spanning targeted therapies, hormonal treatments, and immunotherapies tailored to different subtypes. The fastest-growing category centres on respiratory or lung cancer immunotherapy, showcasing remarkable advancements in addressing historically challenging conditions. The U.S. Oncology Drugs market underscores a commitment to precision medicine and innovative therapeutic approaches, focusing on improving patient outcomes and redefining the standard of care in the complex and diverse cancer treatment landscape. ## **U.S. Oncology DrugsKey Market Players& Competitive Insights** In order to extend their product lines, major market players are substantially investing in research and development, which would propel further growth in the U.S. oncology drugs market. In order to increase their market share, market players are also engaging in a range of strategic initiatives. Notable developments in this regard include the introduction of new products, contracts, mergers and acquisitions, increased investment, and cooperation with other businesses. The American oncology market needs to provide affordable products if it wants to grow and thrive in a more cutthroat and dynamic environment. Major players in theU.S. Oncology Drugsmarket are attempting to increase market demand by investing in research and development operations, including GlaxoSmithKline PIc.,Novartis AG,Merck & Co. Inc.,Eli Lilly and Company,Amgen Inc.,Bayer, Celgene Corporation,Johnson & Johnson,Pfizer Inc. ### **Key Companies in the U.S. Oncology Drugs market include** - GlaxoSmithKline PIc. - Novartis AG - Merck & Co. Inc. - Eli Lilly and Company - Amgen Inc. - Bayer - Celgene Corporation - [Johnson & Johnson](https://www.jnj.com/media-center/press-releases/u-s-food-and-drug-administration-grants-full-approval-for-balversa-to-treat-locally-advanced-or-metastatic-bladder-cancer-with-select-genetic-alterations) - Pfizer Inc. ## **U.S. Oncology Drugs Industry Developments** **May 2023:**AbbVie Inc. announced the U.S. FDA approval for its EPKINLY, among the only drugs for treating patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL). **March 2023:**Pfizer Inc. announced a merger agreement to acquire Seagen, Inc., a global biotechnology company manufacturing cancer medicines. The acquisition would strengthen Pfizer's capabilities and expertise inoncology. **In December 2023**, Absci Corporation, a pioneer in the production of generative artificial intelligence antibodies, entered into a partnership with AstraZeneca to use Absci's Drug CreationTM platform to supply AI-designed antibodies to other pharmaceutical companies. By using AstraZeneca's experience in oncology and Absci's de novo artificial intelligence antibody production platform, the objective is to develop a novel antibody therapeutic for the treatment of cancer. **In February 2024**, ImmunoGen, a biotechnology firm that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer, was purchased by AbbVie Inc. to boost the business's position in the oncology market. **In March of 2024**, Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical business that focuses on developing next-generation radioconjugates (RCs). AstraZeneca agreed to a final agreement to purchase Fusion Pharmaceuticals Inc. This purchase represents a major development in AstraZeneca's attempts to reinvent cancer care by replacing conventional medicines, such as chemotherapy and radiation, with more tailored treatments that seek to improve patient outcomes. These treatments are intended to alleviate the suffering of cancer patients ## **U.S. Oncology Drugs Market Segmentation** ### **U.S. Oncology Drugs Type Outlook** - Chemotherapy - Targeted Therapy - Immunotherapy (Biologic Therapy) - Hormonal Therapy - Other ### **U.S. Oncology Drugs Application Outlook** - Blood Cancer - [Breast Cancer](../../../reports/global-breast-cancer-market-1379) - Gastrointestinal Cancer - Prostate Cancer - Respiratory or Lung Cancer - Other ## Market Drivers ### Growing Cancer Incidence The market is experiencing a notable surge due to the increasing incidence of cancer in the United States. According to the American Cancer Society, approximately 1.9 million new cancer cases are expected to be diagnosed in 2025. This rising trend in cancer cases necessitates the development and availability of effective oncology drugs, thereby driving market growth. The market is likely to expand as healthcare providers seek innovative treatments to address this growing patient population. Furthermore, the aging population, which is more susceptible to various cancers, contributes to this upward trajectory. As a result, pharmaceutical companies are focusing on research and development to create targeted therapies and immunotherapies, which are anticipated to dominate the oncology drugs market in the coming years. ### Emerging Biotech Companies The oncology drugs market is witnessing a surge in the number of emerging biotech companies focused on developing innovative cancer therapies. These companies are often at the forefront of research, utilizing cutting-edge technologies such as gene editing and artificial intelligence to create novel treatments. The presence of these startups fosters a competitive landscape, driving established pharmaceutical companies to enhance their research and development efforts. In 2025, the oncology drugs market is likely to benefit from the influx of new entrants, which may lead to breakthroughs in treatment options. Furthermore, collaborations between biotech firms and larger pharmaceutical companies are becoming increasingly common, facilitating the sharing of resources and expertise, ultimately accelerating the development of effective oncology drugs. ### Increased Healthcare Expenditure The oncology drugs market is positively impacted by the rising healthcare expenditure in the United States. As healthcare spending continues to grow, more resources are allocated towards cancer treatment and research. According to the Centers for Medicare & Medicaid Services, national health expenditure is projected to reach $6.2 trillion by 2028, with a significant portion dedicated to oncology. This increase in funding allows for the development of new oncology drugs and the expansion of treatment options available to patients. Additionally, higher healthcare spending facilitates access to advanced therapies, which may lead to improved patient outcomes. Consequently, The market is expected to thrive as financial resources become more readily available for cancer care. ### Advancements in Precision Medicine The oncology drugs market is significantly influenced by advancements in precision medicine, which tailors treatment based on individual patient characteristics. This approach has gained traction in recent years, leading to the development of targeted therapies that are more effective and have fewer side effects. The National Cancer Institute indicates that precision medicine has the potential to improve treatment outcomes for patients with specific genetic mutations. As a result, pharmaceutical companies are investing heavily in research to identify biomarkers and develop drugs that can specifically target these mutations. This trend is expected to enhance the oncology drugs market, as more personalized treatment options become available, ultimately improving patient survival rates and quality of life. ### Regulatory Support for Drug Approvals The oncology drugs market benefits from robust regulatory support aimed at expediting the approval process for new cancer therapies. The U.S. Food and Drug Administration (FDA) has implemented various initiatives, such as the Breakthrough Therapy designation, which allows for faster development and review of drugs that show promise in treating serious conditions. This regulatory environment encourages pharmaceutical companies to invest in oncology drug development, as they can bring innovative treatments to market more quickly. In 2025, the oncology drugs market is likely to see an influx of new therapies, as the FDA continues to prioritize cancer treatments. This supportive framework not only fosters innovation but also enhances patient access to potentially life-saving medications. ## Future Outlook The oncology drugs market is projected to grow at a 14.2% CAGR from 2025 to 2035, driven by advancements in targeted therapies, increasing cancer prevalence, and enhanced R&D investments. **New opportunities:** - Development of [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937)platforms for tailored oncology treatments. - Expansion of telehealth services for remote patient monitoring and consultations. - Investment in AI-driven drug discovery to accelerate the development of novel therapies. By 2035, the oncology drugs market is expected to achieve substantial growth, reflecting evolving treatment paradigms and technological advancements. ## Segment Insights ### By Type: Chemotherapy Drugs (Largest) vs. Immunotherapy Drugs (Fastest-Growing) In the US oncology drugs market, Chemotherapy Drugs constitute the largest segment, commanding a significant share. These drugs play a critical role in the treatment of various cancers, contributing to their widespread usage across different patient populations. On the other hand, Immunotherapy Drugs, though currently smaller in market share, have been rapidly gaining traction due to their innovative approach in harnessing the immune system to fight cancer, marking a notable shift in treatment strategies. Growth trends in the segment are driven by advances in drug development and increasing investment in oncology research. The rising incidence of cancer among the population, coupled with a shift toward personalized medicine, has fueled demand for both Chemotherapy and Immunotherapy Drugs. While Chemotherapy remains essential for aggressive cancer treatment, Immunotherapy is emerging as a vital option for long-term survival and improved quality of life, highlighting the evolving landscape of oncology therapeutics. Chemotherapy Drugs (Dominant) vs. Targeted Therapy Drugs (Emerging) Chemotherapy Drugs have been the foundation of cancer treatment for decades, showcasing their dominance in the oncology landscape. These drugs, typically used in aggressive interventions, target rapidly dividing cancer cells, thus playing a vital role in various treatment regimens. While they present significant side effects, their effectiveness in shrinking tumors has solidified their presence in standard care. Conversely, Targeted Therapy Drugs represent an emerging trend, focusing on specific cancer cell characteristics. This precision approach minimizes harm to healthy cells, potentially reduces side effects, and enhances efficacy. As research advances, the integration of targeted therapies into treatment protocols is expected to grow, reflecting a shift towards more personalized cancer management. ### By Therapeutic Area: Breast Cancer (Largest) vs. Lung Cancer (Fastest-Growing) In the US oncology drugs market, breast cancer remains the largest segment, commanding a significant market share due to extensive research, high patient prevalence, and innovative treatment options, including targeted therapies and immunotherapies. Following closely is the lung cancer segment, which, while smaller, showcases rapid growth as advancements in personalized medicine and early detection methods gain traction. The prioritization of lung cancer research in recent years is gradually escalating its share in the market. The growth trends for these therapeutic areas are driven by factors such as increasing incidence rates, enhanced clinical trial outcomes, and the introduction of novel therapies. For breast cancer, the consistent development of improvements in medication regimens is keeping treatment options broad and effective. In contrast, lung cancer is experiencing robust growth as a result of rising awareness and screening programs, which are expected to increase the number of patients diagnosed and treated effectively. This dynamic landscape suggests that while breast cancer continues to lead, the opportunities within lung cancer present a rapidly evolving frontier. Breast Cancer: Dominant vs. Lung Cancer: Emerging Breast cancer stands as the dominant therapeutic area within the US oncology drugs market, characterized by significant investment and substantial advances in treatments, including hormonal therapies, chemotherapy, and monoclonal antibodies. Its broad range of available therapies has made it a focal point for pharmaceutical companies, leading to a wealth of options for patients. The segment benefits from a well-established infrastructure for research and support within healthcare systems, with a strong emphasis on patient advocacy and education propelling further advancements. In contrast, lung cancer, marked as an emerging segment, is rapidly gaining attention due to escalating patient numbers and breakthroughs in targeted biologic medications. Innovative treatments focusing on genetic mutations and immune responses are driving its progress, positioning lung cancer as a critical area for future therapeutic advancements and market growth. ### By Route of Administration: Intravenous (Largest) vs. Oral (Fastest-Growing) In the US oncology drugs market, the route of administration plays a crucial role in treatment effectiveness and patient adherence. Intravenous delivery holds the largest market share, largely favored for its rapid onset of action and ability to manage drug interactions effectively. Meanwhile, the oral route is gaining traction due to its convenience and ease of administration, especially for outpatient care, making it a significant player in the market. The growth trends in this segment indicate a notable shift towards oral formulations, driven by ongoing research and development aimed at improving bioavailability and patient compliance. Advances in drug delivery systems and the increasing preference for patient-centric treatment options are propelling the oral route to become the fastest-growing segment. Enhanced absorption and targeted therapeutic effects further underscore the potential of oral administration in the oncology drugs market. Intravenous (Dominant) vs. Oral (Emerging) Intravenous administration of oncology drugs is the dominant route due to its effectiveness in delivering high doses of anticancer therapies directly into the bloodstream, ensuring rapid therapeutic effects. This method is particularly valuable in acute treatment scenarios, such as chemotherapy, where immediate and potent action is required. Additionally, intravenous delivery minimizes issues related to gastrointestinal absorption, offering enhanced predictability in drug pharmacokinetics. On the other hand, oral administration is emerging as a preferred choice for long-term management due to its convenience and reduced hospital visits for patients. This route allows for self-administration, promoting higher adherence to treatment regimens. Continuous innovations in formulation technologies signal a burgeoning future for oral oncology drugs, as they aim to decrease side effects while maintaining efficacy. ### By Patient Demographics: Adult (Largest) vs. Pediatric (Fastest-Growing) The patient demographics segment in the US oncology drugs market is characterized by three main categories: Adult, Pediatric, and Geriatric. The Adult segment holds the largest market share, driven by the higher incidence rates of various cancers within this population. In contrast, the Pediatric segment is gaining traction, attributed to increasing awareness of childhood cancers and advancements in treatment options tailored for younger patients. Growth in the Pediatric segment is being propelled by ongoing research and development efforts focused on effective therapies specifically designed for children. Additionally, supportive regulations and funding for pediatric oncology programs are enhancing treatment accessibility and fostering innovation in this demographic. The Geriatric segment also presents opportunities, influenced by the aging population and the rising prevalence of cancer among older adults. Adult (Dominant) vs. Pediatric (Emerging) The Adult segment remains the dominant force in the US oncology drugs market due to a significant population base affected by various forms of cancer. With established treatment protocols and a broad range of available therapies, this demographic accounts for the majority of drug prescriptions. Conversely, the Pediatric segment is emerging as a critical area of focus, driven by an increase in investment for research and specialized treatments that address the unique oncological needs of children. The expansion of clinical trials for pediatric cancers and the push for more personalized treatment options are enhancing its market presence, indicating a shift in resources and attention towards younger patients. ## Competitive Benchmarking The oncology drugs market is characterized by intense competition and rapid innovation, driven by a growing demand for effective cancer therapies. Key players such as Roche (CH), Bristol Myers Squibb (US), and Merck & Co (US) are at the forefront, each adopting distinct strategies to enhance their market positions. Roche (CH) focuses on personalized medicine, leveraging its robust pipeline of targeted therapies, while Bristol Myers Squibb (US) emphasizes immuno-oncology, aiming to expand its portfolio through strategic acquisitions and partnerships. Merck & Co (US) is heavily investing in research and development, particularly in combination therapies, which positions it well to address diverse patient needs and improve treatment outcomes. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The oncology drugs market appears moderately fragmented, with a mix of established players and emerging biotech firms. The collective influence of these key players shapes the competitive landscape, as they vie for market share through innovation and strategic collaborations. In October 2025, Roche (CH) announced a partnership with a leading biotech firm to co-develop a novel CAR-T cell therapy aimed at treating hematological malignancies. This collaboration is expected to accelerate the development timeline and enhance Roche's capabilities in the CAR-T space, reflecting its commitment to advancing personalized treatment options. The strategic importance of this partnership lies in its potential to strengthen Roche's position in a rapidly evolving segment of the oncology market. In September 2025, Bristol Myers Squibb (US) completed the acquisition of a promising biotech company specializing in next-generation immunotherapies. This acquisition is likely to bolster Bristol Myers Squibb's pipeline and enhance its competitive edge in immuno-oncology, a field that continues to attract significant investment and interest. The move underscores the company's strategy to expand its therapeutic offerings and maintain leadership in innovative cancer treatments. In August 2025, Merck & Co (US) launched a new combination therapy for lung cancer, which has shown promising results in clinical trials. This launch not only reinforces Merck's commitment to addressing unmet medical needs but also positions the company to capture a larger share of the lung cancer treatment market. The strategic importance of this launch is evident in its potential to improve patient outcomes and solidify Merck's reputation as a leader in oncology. As of November 2025, current trends in the oncology drugs market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach market entry and product development, ultimately benefiting patients through improved therapeutic options. ## Recent News & Developments **May 2023:**AbbVie Inc. announced the U.S. FDA approval for its EPKINLY, among the only drugs for treating patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL). **March 2023:**Pfizer Inc. announced a merger agreement to acquire Seagen, Inc., a global biotechnology company manufacturing cancer medicines. The acquisition would strengthen Pfizer's capabilities and expertise inoncology. **In December 2023**, Absci Corporation, a pioneer in the production of generative artificial intelligence antibodies, entered into a partnership with AstraZeneca to use Absci's Drug CreationTM platform to supply AI-designed antibodies to other pharmaceutical companies. By using AstraZeneca's experience in oncology and Absci's de novo artificial intelligence antibody production platform, the objective is to develop a novel antibody therapeutic for the treatment of cancer. **In February 2024**, ImmunoGen, a biotechnology firm that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer, was purchased by AbbVie Inc. to boost the business's position in the oncology market. **In March of 2024**, Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical business that focuses on developing next-generation radioconjugates (RCs). AstraZeneca agreed to a final agreement to purchase Fusion Pharmaceuticals Inc. This purchase represents a major development in AstraZeneca's attempts to reinvent cancer care by replacing conventional medicines, such as chemotherapy and radiation, with more tailored treatments that seek to improve patient outcomes. These treatments are intended to alleviate the suffering of cancer patients ## Report Scope | MARKET SIZE 2024 | 40.29(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 46.01(USD Billion) | | MARKET SIZE 2035 | 173.63(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.2% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche (CH), Bristol Myers Squibb (US), Merck & Co (US), Novartis (CH), Pfizer (US), AstraZeneca (GB), Johnson & Johnson (US), Amgen (US), Gilead Sciences (US) | | Segments Covered | Type, Therapeutic Area, Route of Administration, Patient Demographics | | Key Market Opportunities | Advancements in personalized medicine and immunotherapy are reshaping the oncology drugs market landscape. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the oncology drugs market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall valuation of the US oncology drugs market in 2024?** A: The overall market valuation was $40.29 Billion in 2024. **Q: What is the projected market valuation for the US oncology drugs market by 2035?** A: The projected valuation for 2035 is $173.63 Billion. **Q: What is the expected CAGR for the US oncology drugs market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 14.2%. **Q: Which segment of oncology drugs had the highest valuation in 2024?** A: Targeted therapy drugs had the highest valuation at $12.09 Billion in 2024. **Q: What are the leading therapeutic areas in the US oncology drugs market?** A: Breast cancer and lung cancer are leading therapeutic areas, valued at $8.07 Billion and $7.62 Billion respectively in 2024. **Q: How do oral and intravenous routes of administration compare in terms of market valuation?** A: In 2024, intravenous drugs were valued at $20.12 Billion, significantly higher than oral drugs at $8.07 Billion. **Q: What was the market valuation for pediatric oncology drugs in 2024?** A: The market valuation for pediatric oncology drugs was $8.0 Billion in 2024. **Q: Which company is a key player in the US oncology drugs market?** A: Roche is one of the key players in the US oncology drugs market. **Q: What was the valuation of hormonal therapy drugs in 2024?** A: Hormonal therapy drugs were valued at $8.01 Billion in 2024. **Q: What is the projected growth trend for the US oncology drugs market?** A: The market is expected to grow significantly, reaching $173.63 Billion by 2035. **Q: What will be the market size of Targeted Drugs by 2035?** A: The market size for Targeted Drugs is projected to be 66.5 USD Billion by 2035. **Q: What is the estimated value of Hormonal Drugs in the market for 2024?** A: For the year 2024, the estimated value of Hormonal Drugs is 8.5 USD Billion. **Q: Who are the key players in the US Oncology Drugs Market?** A: Major players include Bristol Myers Squibb, Novartis, AstraZeneca, Merck, and Eli Lilly. **Q: How is the market expected to grow for Other Drugs from 2024 to 2035?** A: The market for Other Drugs is expected to grow from 5.0 USD Billion in 2024 to 20.5 USD Billion in 2035. **Q: What growth opportunities exist in the US Oncology Drugs Market?** A: The market presents growth opportunities through innovation in drug development and increasing prevalence of cancer. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-oncology-drugs-market-14675*